Advertisement

Topics

Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma

19:00 EDT 7 Aug 2017 | Net Resources International

Pharmaceutical firm Calithera Biosciences has begun a Phase II clinical trial of CB-839 in combination with Afinitor (everolimus)‎ for the treatment of patients with renal cell carcinoma (RCC).

Original Article: Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma

NEXT ARTICLE

More From BioPortfolio on "Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...